JP2017006120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017006120A5 JP2017006120A5 JP2016109398A JP2016109398A JP2017006120A5 JP 2017006120 A5 JP2017006120 A5 JP 2017006120A5 JP 2016109398 A JP2016109398 A JP 2016109398A JP 2016109398 A JP2016109398 A JP 2016109398A JP 2017006120 A5 JP2017006120 A5 JP 2017006120A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- molecule
- drb1
- cancer
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 28
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims 8
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims 4
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims 4
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims 4
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000003115 germ cell cancer Diseases 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010225806 | 2010-10-05 | ||
| JP2010225806 | 2010-10-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537718A Division JP6134139B2 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーｔ細胞の活性化方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237964A Division JP2018093870A (ja) | 2010-10-05 | 2017-12-12 | ヘルパーｔ細胞の活性化方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017006120A JP2017006120A (ja) | 2017-01-12 |
| JP2017006120A5 true JP2017006120A5 (cg-RX-API-DMAC7.html) | 2017-05-25 |
| JP6298101B2 JP6298101B2 (ja) | 2018-03-20 |
Family
ID=45927725
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537718A Active JP6134139B2 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーｔ細胞の活性化方法 |
| JP2016109398A Active JP6298101B2 (ja) | 2010-10-05 | 2016-05-31 | ヘルパーｔ細胞の活性化方法 |
| JP2017237964A Pending JP2018093870A (ja) | 2010-10-05 | 2017-12-12 | ヘルパーｔ細胞の活性化方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537718A Active JP6134139B2 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーｔ細胞の活性化方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237964A Pending JP2018093870A (ja) | 2010-10-05 | 2017-12-12 | ヘルパーｔ細胞の活性化方法 |
Country Status (21)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130062368A (ko) | 2003-11-05 | 2013-06-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드 |
| US8765687B2 (en) | 2005-10-17 | 2014-07-01 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| UA101608C2 (uk) | 2007-02-27 | 2013-04-25 | Интэрнэшнл Инститьют Оф Кэнсэр Иммунолоджы, Инк. | Спосіб активації хелперних t-клітин |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| ES2849187T3 (es) * | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| CN104797711B (zh) * | 2012-09-12 | 2018-09-21 | 株式会社癌免疫研究所 | 抗原特异性辅助性t细胞受体基因 |
| SG11201504530VA (en) * | 2012-12-17 | 2015-07-30 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
| ES2832546T3 (es) | 2013-01-15 | 2021-06-10 | Memorial Sloan Kettering Cancer Center | Péptidos WT-1 inmunogénicos y métodos de uso de los mismos |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| RU2668560C2 (ru) | 2013-03-29 | 2018-10-02 | Сумитомо Дайниппон Фарма Ко., Лтд. | Конъюгированная вакцина на основе пептида антигена wt1 |
| JP6005305B2 (ja) * | 2014-02-26 | 2016-10-12 | テラ株式会社 | Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
| KR102588853B1 (ko) | 2014-12-25 | 2023-10-16 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | T 세포 집단의 개변 방법 |
| CN106565836B (zh) * | 2015-10-10 | 2020-08-18 | 中国科学院广州生物医药与健康研究院 | 高亲和力的可溶性pdl-1分子 |
| DK3539974T5 (en) | 2016-11-09 | 2024-05-27 | Univ Osaka | Method for modifying t cell population |
| EP3549957A4 (en) * | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER |
| WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
| EP4036235A1 (en) * | 2018-02-15 | 2022-08-03 | National University Corporation Asahikawa Medical University | Cancer antigen peptide |
| KR20210049119A (ko) * | 2018-08-22 | 2021-05-04 | 프레드 헛친슨 켄서 리서치 센터 | Kras 또는 her2 항원을 표적으로 하는 면역요법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
| ATE420112T1 (de) | 1998-07-31 | 2009-01-15 | Int Inst Cancer Immunology Inc | Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| WO2000018795A2 (en) | 1998-09-30 | 2000-04-06 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| AU2001247220A1 (en) | 2000-02-22 | 2001-09-03 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| DE60224508T2 (de) | 2001-03-22 | 2008-12-24 | International Institute of Cancer Immunology, Inc., Suita-shi | Wti-modifiziertes peptid |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| WO2003002142A1 (fr) | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques |
| EP1447091A4 (en) | 2001-09-28 | 2008-02-13 | Institute Of Can International | NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS |
| JPWO2003028758A1 (ja) | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的ｔ細胞の誘導方法 |
| WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| AU2003262094A1 (en) | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
| JP4480580B2 (ja) | 2002-09-20 | 2010-06-16 | 株式会社癌免疫研究所 | Ｗｔ１置換型ペプチド |
| CA2513701C (en) | 2003-01-15 | 2013-06-18 | Haruo Sugiyama | Dimerized peptide |
| EP1640458B1 (en) | 2003-06-27 | 2011-12-28 | International Institute of Cancer Immunology, Inc. | Method of selecting patients suitable for wt1 vaccine |
| KR20130062368A (ko) | 2003-11-05 | 2013-06-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드 |
| DK1731605T3 (da) | 2004-03-31 | 2010-05-25 | Int Inst Cancer Immunology Inc | Cancerantigenpeptider der er afledt af WT1 |
| US7608769B2 (en) * | 2004-05-12 | 2009-10-27 | First Act, Inc. | Packaged drum set |
| JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| US8765687B2 (en) | 2005-10-17 | 2014-07-01 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| JP4394724B2 (ja) | 2005-11-30 | 2010-01-06 | 株式会社癌免疫研究所 | 新規ペプチド化合物 |
| US7420880B2 (en) | 2005-12-29 | 2008-09-02 | Timex Group B.V. | Multimode electronic device with calibrating/setting mechanism |
| EP2385117B1 (en) | 2006-02-22 | 2016-07-27 | International Institute of Cancer Immunology, Inc. | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| SG177222A1 (en) | 2006-12-28 | 2012-01-30 | Int Inst Cancer Immunology Inc | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| UA101608C2 (uk) | 2007-02-27 | 2013-04-25 | Интэрнэшнл Инститьют Оф Кэнсэр Иммунолоджы, Инк. | Спосіб активації хелперних t-клітин |
| EP3173480A3 (en) | 2007-03-05 | 2017-08-16 | International Institute of Cancer Immunology, Inc. | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| ES2849187T3 (es) * | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
| SG11201504530VA (en) | 2012-12-17 | 2015-07-30 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
-
2011
- 2011-10-04 ES ES11830662T patent/ES2849187T3/es active Active
- 2011-10-04 MY MYPI2013001197A patent/MY170306A/en unknown
- 2011-10-04 EA EA201390509A patent/EA037547B1/ru unknown
- 2011-10-04 CN CN201610191489.4A patent/CN105802910A/zh active Pending
- 2011-10-04 CN CN201180058552.2A patent/CN103298928B/zh active Active
- 2011-10-04 BR BR112013008230A patent/BR112013008230A2/pt not_active Application Discontinuation
- 2011-10-04 JP JP2012537718A patent/JP6134139B2/ja active Active
- 2011-10-04 WO PCT/JP2011/072874 patent/WO2012046730A1/ja not_active Ceased
- 2011-10-04 TW TW100135857A patent/TWI608099B/zh active
- 2011-10-04 AU AU2011313327A patent/AU2011313327B2/en active Active
- 2011-10-04 SG SG10202108581TA patent/SG10202108581TA/en unknown
- 2011-10-04 CA CA2813557A patent/CA2813557C/en active Active
- 2011-10-04 KR KR1020137011554A patent/KR20140009168A/ko not_active Ceased
- 2011-10-04 MX MX2013003884A patent/MX361299B/es active IP Right Grant
- 2011-10-04 AR ARP110103676A patent/AR083295A1/es unknown
- 2011-10-04 US US13/877,768 patent/US10654892B2/en active Active
- 2011-10-04 KR KR1020207004213A patent/KR102171794B1/ko active Active
- 2011-10-04 KR KR1020197008457A patent/KR102079480B1/ko not_active Expired - Fee Related
- 2011-10-04 NZ NZ703560A patent/NZ703560A/en unknown
- 2011-10-04 NZ NZ609460A patent/NZ609460A/en unknown
- 2011-10-04 TW TW105107752A patent/TW201623616A/zh unknown
- 2011-10-04 SG SG2013025622A patent/SG189287A1/en unknown
- 2011-10-04 EP EP11830662.0A patent/EP2626418B8/en active Active
- 2011-10-04 SG SG10201508252PA patent/SG10201508252PA/en unknown
- 2011-10-04 PH PH1/2013/500654A patent/PH12013500654A1/en unknown
-
2013
- 2013-04-02 IL IL225536A patent/IL225536B/en not_active IP Right Cessation
- 2013-04-05 MX MX2018008436A patent/MX2018008436A/es unknown
- 2013-04-25 ZA ZA2013/03056A patent/ZA201303056B/en unknown
- 2013-05-03 CO CO13111246A patent/CO6710946A2/es unknown
-
2016
- 2016-05-03 IL IL245440A patent/IL245440A0/en unknown
- 2016-05-31 JP JP2016109398A patent/JP6298101B2/ja active Active
-
2017
- 2017-12-12 JP JP2017237964A patent/JP2018093870A/ja active Pending
-
2020
- 2020-03-31 US US16/835,761 patent/US12415833B2/en active Active